Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival
about
Treatment of Gram-positive infections in critically ill patientsPerspective on optimizing clinical trials in critical care: how to puzzle out recurrent failuresCurrent and Future Considerations for the Treatment of Hospital-Acquired PneumoniaSystematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer?Update on the emerging role of telavancin in hospital-acquired infectionsATS Core Curriculum 2014: part I. Adult pulmonary medicine.Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogensVancomycin revisited - 60 years laterThe role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia.Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia.Emerging drugs for nosocomial pneumonia.Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options).Bacterial Pneumonia in Patients with Cancer: Novel Risk Factors and Management.Controversies and advances in the management of ventilator associated pneumonia.Comparative efficacy of telavancin and daptomycin in experimental endocarditis due to multi-clonotype MRSA strains.Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality.Once-Daily Treatments for Methicillin-Susceptible Staphylococcus aureus Bacteremia: Are They Good Enough?Telavancin for the treatment of methicillin-resistant Staphylococcus aureus infections.
P2860
Q27015976-3D4C5230-AC95-4BB0-A2FE-3E3C5AD422EAQ28069198-85DB9357-8F9D-4500-9DA1-8B170AE6E96EQ28071882-24B93C10-1D09-49A8-A082-E7AE7FDC3C65Q28078557-3C9D8582-34A6-4CB4-8BE7-FDCAB52CC740Q28083522-3F712A33-722E-490B-9B2D-D7DDF7F0925BQ33786162-771DDE72-B790-4DD5-9E2B-499C73B42771Q33788308-97CBEE6A-BDC2-4B5B-BDD3-D3876EF0853BQ34433066-A6A485EC-A52E-4090-A0E9-CD5635D7C3D5Q34672655-9BB21467-CFB2-4D9F-8EE0-857847833BD0Q34677611-00CEB270-EAEA-441E-8CF2-9E2C72D66DCCQ36078359-46C19131-01B9-4E31-AFBF-679CE6EF1BA1Q38468392-7A3170FC-2148-47A0-8490-7DDAF1FC13DBQ38575714-BB65A937-D182-4364-975A-42470D932A1AQ38646905-71667711-8DC7-477C-B4E4-8C12884B9F44Q38829519-AEED7DE1-76EB-48F2-9664-399962705EFFQ38878167-28C41E7F-F7CF-4645-8E33-923751269B6BQ38907793-A86F1FAD-07E7-4DB7-AC49-FD18CA92C0CCQ39287519-A9810937-F586-4D14-8F60-030500E14CD3Q40054170-DA4B6E96-93D2-4F14-AC9C-410DA315E091Q40633251-909A7FF7-7819-48E1-9E7D-48C0752BC512Q41028133-F7DC5F18-D78A-42D0-B563-B307CACA2C03Q41994740-48218199-30C4-49F7-A6C5-B04C4300F4EFQ53823457-2205FC30-BAF2-4A1C-A4E2-A5F0CA4BA8A5
P2860
Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival
@ast
Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival
@en
type
label
Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival
@ast
Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival
@en
prefLabel
Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival
@ast
Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival
@en
P2093
P2860
P356
P1476
Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival
@en
P2093
Alan Hopkins
Andrew F Shorr
Ethan Rubinstein
G Ralph Corey
Martin E Stryjewski
Steven L Barriere
P2860
P304
P356
10.1128/AAC.02330-13
P407
P577
2014-01-13T00:00:00Z